-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 3, the application for the clinical trial of the 3D-229 injection of Silide Di's AXL inhibitor was officially accepted by CDE, and it was the first AXL inhibitor to be declared for clinical use in China.
3D-229 (AVB-500), developed by Aravive of the United States, on November 11, 2020, Sidi Di obtained the exclusive development and commercialization rights of 3D-229 in the oncology field of Greater China from Aravive for a total of 219 million US dollars.
The GAS6-AXL signaling pathway is a key pathway that promotes tumor growth and metastasis, tumor immune escape and drug tolerance.
The advantage of AVB-500 is that it has a high affinity for GAS6 ligand, which solves the problem of low selectivity of TKI inhibitors targeting AXL, resulting in off-target toxicity, tumor cell resistance, and low affinity of monoclonal antibodies.
Previously, AVB-500 has shown potential efficacy in a phase Ib clinical trial for patients with platinum-resistant ovarian cancer (PROC).
At present, clinical trials of AVB-500 for renal cell carcinoma and urothelial cancer are also underway, and it has obtained fast-track qualification granted by the FDA for platinum-resistant recurrent ovarian cancer indications.
Source: Aravive official website
